Global Insulin API Sales Market Report 2020

Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
Insulin API is a relatively concentrated industry in China, The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi several companies but their products are for their own use. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API

Market Analysis and Insights: Global Insulin API Market
The global Insulin API market size is projected to reach US$ 2441.2 million by 2026, from US$ 1896.3 million in 2020, at a CAGR of 4.3% during 2021-2026.

Global Insulin API Scope and Market Size
The global Insulin API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Insulin API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Insulin API market is segmented into
Regular Human Insulin
Insulin Analogue

Segment by Application, the Insulin API market is segmented into
Fast-acting
Premix
Long-acting

The Insulin API market is analysed and market size information is provided by regions (countries). Segment by Application, the Insulin API market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Insulin API Market Share Analysis
Insulin API market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Insulin API business, the date to enter into the Insulin API market, Insulin API product introduction, recent developments, etc.

The major vendors covered:
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
United Laboratory
Biocon
Torrent Pharma
Amphastar
Ganlee
Julphar Diabetes
Wockhardt